Varian Medical Systems Announces Acquisition of Certain Assets of Transpire, Inc., a Specialized Developer of Radiation Simulation Software

PALO ALTO, Calif., Aug. 5, 2014 /PRNewswire/ -- Varian Medical Systems, Inc., (NYSE: VAR) today announced it has acquired certain assets of Transpire, Inc., including the Acuros® dose calculation software that has been integrated into Varian's market-leading BrachyVision™ and Eclipse™ treatment planning software products.

"Acuros software makes it possible to implement highly precise forms of treatment in heterogeneous tissues such as the lung—something other algorithms do not do as well," says Jeff Amacker, Varian's senior director of clinical solutions.  "Acuros can accomplish this in a workable timeframe, compared with more cumbersome Monte Carlo approaches that are just not used because they take too long."

"Varian and Transpire have enjoyed an OEM relationship since 2008, when we first incorporated the Acuros algorithm into our systems for planning and delivering high-precision radiotherapy for the treatment of cancer," says Kolleen Kennedy, president of Varian's Oncology Systems business.  "This acquisition will enable us to continue leveraging the Acuros solution for use in proton therapy, and for improving our image guidance tools on other Varian treatment systems.  We look forward to working directly with Transpire's accomplished team of engineers and scientists, who have now joined the Varian team, to further refine and enhance our treatment planning software systems."

The acquisition also covers Transpire's Attila™ software, which is in use worldwide in a diverse range of industries where radiation effects play an integral role in product performance, safety, and reliability.

"We plan to integrate Attila software with our products for security and inspection applications," says Sunny Sanyal, president of Varian's Imaging Components Businesses.  "It will enable us to provide comprehensive solutions for customers that integrate Varian's high-energy X-ray technology into systems for cargo screening, industrial inspection and non-destructive testing."

Varian will continue developing the Acuros and Attila software products with the Transpire team.  "We are very pleased that the Transpire team has joined our organization," said Dow Wilson, Varian CEO.  "This is a world-class group of scientists with deep experience at the intersection of nuclear engineering and software development.  We believe that they will help us continue fulfilling our mission of providing customers with empowering software solutions."

The acquisition closed at the end of July. 

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 6,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world.  For more information, visit http://www.varian.com or follow us on Twitter.

Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry and market outlook, including customer demand and acceptance of products or technology; growth drivers; the company's future orders, revenues or other financial performance; the ability of the company's technology and products to treat cancer; and any statements using the terms "believe," "will," "future," "continue," "plan," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the ability to effectively integrate the products of Transpire into the company's product offerings and sales and marketing operations; the ability to retain the services of key Transpire personnel; demand for the company's and Transpire's products; the company's ability to develop, commercialize, and deploy new products; the impact of competitive products and pricing; the effect of global economic conditions; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:
Meryl Ginsberg, Tel: 650-424-6444
[email protected]

SOURCE Varian Medical Systems, Inc.